BioPorto Diagnostics A/S is a leading in vitro diagnostics company dedicated to saving lives and enhancing the quality of life through actionable biomarkers. BioPorto Diagnostics A/S empowers clinicians to make informed decisions in patient management with its innovative tools and expertise.
Based in Copenhagen, DK, and with facilities at 117 4th Avenue, Suite 202, Needham, MA 02494, US, BioPorto Diagnostics A/S leverages its extensive knowledge in antibody and assay development, coupled with its advanced platform, to develop a robust pipeline of novel products. These products address critical unmet medical needs, ultimately improving clinical and economic outcomes for patients, providers, and the broader healthcare ecosystem. BioPorto Diagnostics A/S flagship products, built upon the NGAL biomarker, are designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI). By providing clinicians with rapid insights into patients at risk of AKI, BioPorto enables earlier intervention and tailored patient management strategies.
BioPorto Diagnostics A/S is committed to advancing healthcare through innovative diagnostic solutions. We invite the manager of BioPorto Diagnostics A/S to create a customized and exclusive company showcase and product listing on our platform to further highlight their contributions to the medical field.
Other organizations in the same industry
This company is also known as